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Numerous studies have implicated the abnormal accumulation of intraneuronal amyloid-β (Aβ) as an important
contributor to Alzheimer’s disease (AD) pathology, capable of triggering neuroinflammation, tau hyperphosphorylation
and cognitive deficits. However, the occurrence and pathological relevance of intracellular Aβ remain a matter of
controversial debate. In this study, we have used a multidimensional approach including high-magnification and
super-resolution microscopy, cerebro-spinal fluid (CSF) mass spectrometry analysis and ELISA to investigate the Aβ
pathology and its associated cognitive impairments, in a novel transgenic rat model overexpressing human APP. Our
microscopy studies with quantitative co-localization analysis revealed the presence of intraneuronal Aβ in transgenic
rats, with an immunological signal that was clearly distinguished from that of the amyloid precursor protein (APP) and
its C-terminal fragments (CTFs). The early intraneuronal pathology was accompanied by a significant elevation of
soluble Aβ42 peptides that paralleled the presence and progression of early cognitive deficits, several months prior to
amyloid plaque deposition. Aβ38, Aβ39, Aβ40 and Aβ42 peptides were detected in the rat CSF by MALDI-MS analysis
even at the plaque-free stages; suggesting that a combination of intracellular and soluble extracellular Aβ may be
responsible for impairing cognition at early time points. Taken together, our results demonstrate that the intraneuronal
development of AD-like amyloid pathology includes a mixture of molecular species (Aβ, APP and CTFs) of which a
considerable component is Aβ; and that the early presence of these species within neurons has deleterious effects in
the CNS, even before the development of full-blown AD-like pathology.
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Alzheimer’s disease (AD) remains the most common form
of age-related dementia, a disorder which affects approxi-
mately 36 million sufferers worldwide [1]. Recent studies
have revealed the existence of a long asymptomatic phase,
where the pathological changes leading to AD begin –at
least- decades before the first symptoms of cognitive de-
cline appear [2-4].* Correspondence: claudio.cuello@mcgill.ca
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unless otherwise stated.Although these studies have addressed the temporal
order in which AD pathological hallmarks appear, the exact
sequence of cellular and molecular events that lead to AD
is still poorly understood. However, it is widely accepted
that before the overt deposition of amyloid plaques and
neurofibrillary tangles, the accumulation of amyloid-β (Aβ)
peptides is one of the first steps in the series of pathogenic
changes that lead to neurodegeneration and dementia [5,6].
The concept of a pre-clinical, asymptomatic phase of AD
is gaining increasing support. This is best evidenced by the
recent revision of research diagnostic criteria, which now
include a new detailed framework for the diagnosis and
pre-clinical staging of individuals at-risk [7]. Notably, little
is known about this early phase, as most studies of the ADd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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clinical period deserves further attention, as it should offer
a critical window for successful treatment.
Given the lack of definitive AD biomarkers in humans,
transgenic animal models of the amyloid pathology continue
to be valuable tools to examine molecular changes preceding
the deposition of amyloid plaques and associated pathology
(i.e. late inflammation, neuritic dystrophy, etc.). For instance,
many studies in transgenic models have demonstrated that
Aβ accumulates first intraneuronally, before amyloid plaques
appear [8-13]; a finding that has been validated in post-
mortem AD and Down syndrome (DS) brains [14-20].
A deeper understanding of the pre-plaque stage is of
great relevance in view of the fact that the intraneuronal
compartment is also a place where Aβ can oligomerize
[10,21,22] forming toxic aggregates which can impair syn-
aptic plasticity [23-26], induce cognitive impairments
[27,28] and unleash a pro-inflammatory reaction [10,29].
In fact, the nature and pathological relevance of the intra-
cellularly accumulated material have been questioned in a
recent study [30], raising the intriguing possibility that
such material is APP, rather than Aβ. The arguments re-
garding this controversy have been recently reviewed [31].
The idea that the intraneuronal material is only APP is a
challenging proposition, and we therefore considered that
this issue deserved a thorough, multidisciplinary analysis.
For such study, we have used the McGill-R-Thy1-APP
transgenic rat, which is unique compared to other ro-
dent models in that the AD-like phenotype has been
achieved with a single genomic insertion of a mutated
human APP transgene; minimizing off-target genetic
corruption and therefore being closer to the human dis-
ease [32]. Our microscopy studies at high magnification
and high resolution have revealed a clear segregation be-
tween Aβ-immunoreactivity and that of APP and its
C-terminal fragments (CTFs). Soluble Aβ40 and Aβ42
peptides were observed elevated early, in cortex and
hippocampus from transgenic rats. The increase in Aβ
peptides paralleled the manifestation of cognitive defi-
cits, several months prior to amyloid plaque deposition.
Notably, Aβ38, Aβ39, Aβ40 and Aβ42 peptides could be
detected in the rat cerebro-spinal fluid (CSF) by
MALDI-MS analysis, even at plaque-free stages. Taken to-
gether, these results indicate that the early, intracellular
accumulation of soluble Aβ in McGill transgenic rats is
already accompanied by a CNS compromise (i.e. learning
and memory impairments). Further to it, we have demon-
strated that the early CNS amyloid pathology is reflected
and can be monitored in the rat CSF.
Materials and methods
Animals
Transgenic rats belonged to the McGill-R-Thy1-APP
line, harboring the human APP751 transgene with theSwedish and Indiana mutations under the control of the
murine Thy1.2 promoter [11]. The 3-month old group
consisted of: transgenic heterozygote (n = 7) and homozy-
gote (n = 7) rats and non-transgenic (n = 10) littermates.
The 7-month old group consisted of: transgenic homozy-
gote (n = 4) and non-transgenic (n = 4) littermates. The
13-month old group consisted of: transgenic heterozygote
(n = 10) and homozygote (n = 6) rats and non-transgenic
(n = 10) Wistar rats (Charles River, Wilmington, MA),
housed in identical conditions. Each group had equal gen-
der representation. Animals were maintained on a 12-
hour light/12-hour dark cycle and had ad libitum access
to water and a standard rodent diet. All procedures were
approved beforehand by the Animal Care Committee of
McGill University, following the guidelines of the Canad-
ian Council on Animal Care.
Tissue and CSF collection
Rats were deeply anesthetized with equithesin, and CSF
(~80-150 μl) was collected from the cisterna magna
using a glass capillary and subsequently frozen at −80°C,
following an established protocol [33]. Only clear, blood-
free CSF was used for analysis.
For tissue collection, the animals were perfused transcar-
dially with cold saline for 1 min. The brain was removed,
one hemisphere was kept for immunohistochemistry (IHC)
and the other was dissected, flash-frozen and kept at −80°C
for further neurochemical analysis. The hemisphere for
IHC was immersion-fixed in cold 4% paraformaldehyde in
0.1 M phosphate buffer (PB) for 24 h and transferred to
30% sucrose in 0.1 M PB. After the brains equilibrated in
sucrose, they were cut into 40 μm coronal sections with a
freezing microtome (Leica SM 2000R, Germany). Brain sec-
tions were stored in cryoprotectant solution (37.5% v/v
ethylene glycol, 37.5% w/w sucrose, in PBS pH 7.4)
at −20°C until processed for IHC.
Antibodies
A detailed description of the primary antibodies used in
this study can be found in Table 1.
Bright-field immunohistochemistry
Free-floating immunostaining was done following well-
established protocols [10,11,34,35]. Sections were incu-
bated in 0.3% hydrogen peroxide in PBS for 20 min,
washed in PBS-T (0.01 M phosphate-buffered saline,
0.2% Triton X-100) and blocked 1 h with 10% normal
goat serum (NGS) in PBS-T. To examine the evolution
of the AD-like amyloid pathology we incubated sections
with the monoclonal antibody McSA1 [36] (MediMabs,
Montreal, Canada) at 1:4000 in PBS-T with 5% NGS
overnight at 4°C. The following day, the sections were
washed in PBS-T and incubated with a goat anti-mouse
secondary antibody (MP Biochemicals, Canada) 1:100 in
Table 1 List of antibodies used in this study
Antibody name Antibody target Source Epitope recognized Obtained from
McSA1 Human Aβ Mouse monoclonal N-terminus of human Aβ (residues 1–12) Medimabs, Canada
MOAB-2 Human Aβ Mouse monoclonal N-terminus of human Aβ (residues 1–4) Biosensis, Australia
Nu1 Human Aβ oligomers Mouse monoclonal Conformational, Aβ oligomers Dr. William Klein, Northwestern University
pab27576 APP Rabbit polyclonal Last 43 C-terminal residues of APP Dr. Gerhard Multhaup, McGill University
W0-2 Human Aβ Mouse monoclonal N-terminus of human Aβ (residues 4–10) EMI Millipore, USA
G2-10 Human Aβ40 Mouse monoclonal C-terminus of Aβ40 EMI Millipore, USA
G2-13 Human Aβ42 Mouse monoclonal C-terminus of Aβ42 EMI Millipore, USA
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PBS and incubated for 1 h with a mouse anti-peroxidase
monoclonal antibody [37] (1:30) pre-incubated with horse-
radish peroxidase (5 μg/ml) in PBS (MAP kit, Medimabs,
Canada). Stainings were developed with 0.06% 3,3′-diami-
nobenzidine (Sigma-Aldrich, USA) and 0.01% hydrogen
peroxide (Sigma-Aldrich, USA) in PBS and then mounted
on subbed slides. Sections were dehydrated in increasing
ethanol concentrations (70-100%) and xylene, prior to cov-
erslipping with Entellan (EM Science, USA). Images were
acquired on an Axioplan Imaging microscope equipped
with an AxioCam HRc digital camera (Carl Zeiss, Toronto,
Canada); using the Axiovision 4.8 Software.
Immunofluorescence and confocal microscopy
Immunofluorescence was done following established
protocols [10,38]. Sections were incubated in 50% etha-
nol for 20 min followed by three 10-min washes in PBS.
Blocking was done in 10% NGS in PBS-T during 1 h.
Primary antibodies were incubated overnight in 5% NGS
at 4°C. Double labeling was performed between three
anti-Aβ antibodies (McSA1, Medimabs, Canada; MOAB-2
[39], Biosensis, Australia and Nu1 [40], provided by Dr.
William Klein, Northwestern University, USA; at 1:500)
and a polyclonal antibody (pab27576, provided by Dr.
Gerhard Multhaup, McGill University; at 1:500) di-
rected against the last 43 amino acids of the C-terminal
domain of APP. This antibody recognizes full-length
APP (~100 kDa) and CTFs (~12 kDa) without cross-
reactivity for Aβ [13,41,42]. Alexa 488-conjugated goat
anti-mouse (Jackson Immunoresearch, USA) and Alexa
594-conjugated goat anti-rabbit (Molecular Probes,
USA) secondary antibodies were applied overnight at
1:400–1:800 in PBS with 5% NGS. Sections were washed
three times in PBS and subsequently mounted on gelatin
subbed slides, dried overnight at 4ºC, and coverslipped
with Aqua Polymount (Polysciences, USA).
Images were taken on a Zeiss LSM 510 confocal
microscope (Carl Zeiss, Canada) equipped with Argon
and Helium-Neon lasers. Three sections per animal were
immunolabeled and five pictures per animal (per region)
were acquired from area CA1 of the hippocampus andlamina V and III of the parietal cortex. To maximize the
sensitivity of co-localization analysis and fully exploit the
resolution of the microscope objective (Zeiss 63X oil
immersion objective NA = 1.4), we used a 3.0 scan zoom
so that each pixel covered 0.05 μm. Each signal was ac-
quired using separate tracts with the appropriate laser-
filter settings to avoid bleed-through of signals, and the
pinhole was set so that optical sections were less than
0.7 μm thick. With the given objective settings, the the-
oretical resolution was of 250 nm in x, y and 700 nm in
the z plane.
Confocal images were analyzed and quantified with the
JACoP plugin [43] of the Image J software, to obtain Pear-
son and Manders’ correlation coefficients. The Pearson
coefficient defines the quality of the linear relationship be-
tween two signals and varies between 1 and −1. Manders’
coefficients (M1 and M2) indicate the proportion of signal
overlap; varying from 0 (no co-localization) to 1 (perfect
co-localization). In this study, M1 indicated the propor-
tion of McSA1 (or MOAB-2 or Nu1) (green signal)
overlapping pab27576 immunoreactivity (red signal)
over its total intensity. Conversely, M2 is defined as
the proportion of pab27576 signal (red) overlapping
McSA1/MOAB-2/Nu1 immunolabels (green) over its
total intensity. Omission of primary antibodies resulted
in no detectable fluorescent staining (data not shown).
Structured Illumination Microscopy (SIM)
Given that both McSA1 and pab27576 gave robust fluor-
escent signals, we were able to image them by SIM a
super-resolution microscopy technique permitting a
resolution of ~100 nm in x, y and of ~300 nm in z [44].
The IHC was done following the same protocol as for
the confocal experiments, except that the McSA1 and
pab27576 were used at a concentration of 1:1000. Images
were taken on a DeltaVision OMX V4 Blaze super-
resolution microscope (Applied Precision, GE Healthcare).
Reconstructed images were visualized using the Volocity
3D Image Analysis Software (PerkinElmer, USA). Following
image reconstruction and registration, serial z planes were
assembled to form a 3D model using the Volocity Software.
A video showing different rotations and magnifications of
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software (Additional file 1: Video).
Human Aβ40 and Aβ42 ELISA
Brains were homogenized in 8% vol (w/v) of cold TBS
buffer (150 mM NaCl, 50 mM Tris / HCl, 5 mM EDTA,
pH 7.6) containing a protease inhibitor cocktail (Roche,
Germany) using a teflon-glass homogenizer. Homogenates
were cleared by centrifugation at 100.000 g for 1 h at 4°C,
and supernatants were collected for further analysis (TBS-
soluble fraction). The remaining pellets were dissolved in
70% formic acid (FA) with 50% of homogenization volume
and sonicated for 30 s at 30% power. Centrifugation at
100.000 g was repeated and supernatants were collected
(FA-soluble fraction). Samples from FA-soluble fractions
were neutralized with 1 M Tris, 0.5 M Na2HPO4 prior to
ELISA analysis.
Levels of Aβ40 or Aβ42 in TBS-soluble and FA-soluble
fractions were determined by sandwich ELISA. The C-
terminus-specific anti-Aβ monoclonal antibodies G2-10
and G2-13 (EMI Millipore, USA) were used to capture Aβ
species terminating at 40 or 42 amino acids, respectively.
The monoclonal biotinylated W0-2 (EMI Millipore, USA)
recognizing the Aβ N-terminus was used as detection
antibody, and the reaction was developed by streptavidin-
horseradish peroxidase conjugate and the chromogenic
substrate 1-Step Ultra-TMB (Pierce, USA). After stopping
the reaction with 1 M H2SO4, the enzymatic products
were measured at 450 nm in a microplate reader (Anthos
HT2, Germany). Synthetic Aβ40 or Aβ42 peptides (EMI
Millipore, USA) served as standards.
MALDI-MS analysis of Aβ peptides in rat CSF
Aβ was immunoprecipitated from 50 μl CSF with 5 μg
of the anti-Aβ antibody W0-2 (EMI Millipore, USA)
coupled to protein-G sepharose beads (GE Healthcare,
USA) and incubated overnight at 4°C. The beads were
washed three times with PBS and twice with 50 mM am-
monium acetate, pH 7.0. Aβ was eluted twice with 50%
acetic acid and vacuum-dried overnight. Immunopreci-
pitated samples were resuspended in 10 μl of TA (33%
acetonitrile, 0.1% trifluoroacetic acid) and sonicated in a
water bath for 10 min. Samples were spotted by the
dried droplet technique mixing 1 μl of sample with 1 μl
of a TA solution saturated with sinapinic acid. MALDI-
MS analysis was carried out on a Bruker Ultraflex II in-
strument (Bruker Daltonik, Bremen, Germany).
Behavioral studies
Tests were conducted during the light phase of the cir-
cadian cycle. Rats were handled prior to testing for 2–3
days. Experimenters were blinded to the genotype during
all behavioral studies.Fear conditioning
The fear conditioning protocol was designed adapting a
previously reported procedure [45]. Animals were tested
in a single chamber connected to a weight transducer
system to allow the tracking of movement (Panlab,
Spain). The chamber was scented with coconut extract
and cleaned with ethanol 70% between animals. To cre-
ate a different environment for the fear memory reten-
tion test, the walls of the chamber were decorated with
visual cues; the chamber was scented with mint extract
and cleaned with acetic acid 1% between animals.
On day 1 (habituation) rats were allowed to explore
the chamber for 5 min and returned to their home
cages. On day 2 (conditioning), after an initial 90 sec
phase of exploration (baseline), a 30 sec tone (75 dB,
5 kHz) was presented which co-terminated with a 2 sec
foot shock (0.75 mA). Animals were allowed to recover
(post-shock; 120 sec) and returned to their home cages.
On day 3, contextual fear conditioning was evaluated by
placing the animals in the chamber during 8 min. On
day 4, animals were allowed to explore the “new” arena
for 120 sec (baseline). This was followed by three con-
secutive tone presentations (30 sec, 75 dB, 5 kHz), each
separated by a 30 sec pause. The Freezing software
(Freezing v1.3.01, Panlab) recorded all freezing episodes
in each of the test phases, considering freezing as immo-
bility for at least 2 sec.Novel object recognition and location
Before testing, the animals were habituated to the testing
environment by allowing them to explore the experi-
mental arena. Following habituation, the rats were sub-
jected to three testing phases: Exploration, Novel Object
Location (NOL) and Novel Object Recognition (NOR).
During exploration, five objects similar in size but differ-
ent in color, shape and texture were put in the arena.
These objects have been tested in pilot studies to ensure
that none of them elicited spontaneous preference or
avoidance. The animals were allowed to explore the ob-
jects for three sessions of 2 min, with a 10 min inter-
session interval. An animal was considered as exploring
when the muzzle was touching or in close proximity to
the objects. The NOL test consisted of a single 2 min
session where one of the objects was moved to a new lo-
cation. For NOR, one of the undisplaced objects was
substituted by a novel one. For NOL and NOR, the time
exploring familiar and displaced/novel objects was re-
corded separately to calculate the discrimination ratio.
We defined this ratio as the difference in exploration
time for the displaced or novel object divided by total
exploration time. Increased time spent exploring the ob-
ject in the novel location was interpreted as successful
spatial memory. Increased time spent exploring the novel
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for the familiar objects versus the novel one.
Calculation of cognitive index
For correlation analysis between behavior and Aβ path-
ology, a global learning and memory score, referred as
cognitive index, was calculated based on the animals’
performance during each different phase of behavior
tests. For auditory and cue fear conditioning, a score
was computed by calculating the fold increase in freez-
ing behavior during the post-shock phase and tone pres-
entation (respectively), compared to baseline freezing.
Context conditioning freezing percentages were con-
verted to a 10-point scale. For NOL and NOR, a score
was obtained by calculating the fold increase between
the animal’s discrimination ratio and that of chance
levels. All behavior scores were added and expressed as
a z score, referred here as “cognitive index”.
Von Frey test
Animals were habituated to the testing environment by
placing them in individual boxes on a metal mesh floor
during 10 min. The following day mechanical sensitivity
was assessed by measuring withdrawal responses to a
series of calibrated Von Frey filaments with increment-
ing force (15 g, 26 g, 60 g and 100 g). These were ap-
plied perpendicularly to the plantar surface of both hind
paws, following the “up and down” method [46]. Each
hind paw was poked twice, calculating an average of all
four pokes for between-animal comparisons.
Statistical analysis
The software Graph Pad Prism 5.01 (La Jolla, CA, USA)
was used for statistical analysis. One-way ANOVA was
used for three-group comparisons, followed by post-hoc
multiple comparison tests (as specified in figure legend).
Two-way ANOVA was used to analyze the fear condi-
tioning data. Graphs illustrate mean ± SEM.
Results
Progression of the amyloid pathology in
McGill-R-Thy1-APP transgenic rats
This study provides a quantitative biochemical and
morphological investigation of the evolution of the Aβ
pathology and its associated cognitive impairments in
McGill-R-Thy1-APP rats. In this rat model, the expres-
sion of Aβ-immunoreactive material is detectable as
early as 1 week of age and the first isolated amyloid pla-
ques may appear between 6 – 8 months starting in the
subiculum [11].
We defined the pre-plaque stage of the amyloid path-
ology as a stage where Aβ immunoreactivity is limited to
the intraneuronal compartment in the absence of extra-
cellular amyloid plaques, as detected with the anti-AβMcSA1 monoclonal antibody (Figure 1). In this cohort,
3 and 7 month-old McGill transgenic rats displayed robust
intracellular McSA1 immunoreactivity and no evidence of
amyloid plaque deposition (Figure 1). By 13 months, homo-
zygote (+/+) animals displayed widespread and abundant
amyloid plaques throughout the cortex (with greatest ex-
pression in lamina V) (Figure 1c, i), hippocampus (Figure 1
c, f) and amygdala (Figure 1l). Heterozygote transgenic rats
of comparable age (13 months) did not exhibit amyloid pla-
ques (Figure 1n, o). In this rat model, the amyloid path-
ology at advanced stages (18–20 months) is further
accompanied by strong microglial activation and dystrophic
neuries surrounding amyloid plaques [11]. Absence of
McSA1-immunoreactivity was observed in non-transgenic
animals (Figure 1m), at all time points examined.
Quantitative co-localization analysis between Aβ and
APP/CTF-specific signals
To detect intracellular Aβ we utilized the monoclonal
antibody (McSA1), which recognizes the N-terminal re-
gion of the human Aβ peptide (residues 1–12) [36]. This
epitope could theoretically be found as well in β-CTF
and in the APP molecule. However, competition studies
have demonstrated that the McSA1 antibody is highly
specific for Aβ as opposed to APP or sAPP-α [11,36].
We performed quantitative co-localization analysis be-
tween McSA1 and pab27576 immunoreactivities with the
JACoP/Image J software (Figure 2a), at pre- and post-
plaque stages of the amyloid pathology. At 3 months of
age (pre-plaque stage) we observed only a partial co-
localization between McSA1 and pab27576 immunoreac-
tivity in neurons from lamina V (Figure 2b), as reflected
by an average Pearson coefficient of 0.44 ± 0.03 (Table 2).
Quantitative analysis demonstrated only ~30% overlap
(M1 = 0.30 ± 0.03) between McSA1 and pab27576 signals
in lamina V neurons (Table 2), indicating that ~70% of the
cellular epitope recognized by McSA1 is not coming from
APP or β-CTFs. Similar observations were made in CA1
neurons and in neurons from lamina III of the cortex
(Additional file 2: Figure S1), revealing Pearson coeffi-
cients of 0.57 ± 0.02 and 0.32 ± 0.03 and a degree of over-
lap of only ~ 20 – 50% between the two signals (M1 =
0.48 ± 0.02 and M1 = 0.23 ± 0.03; respectively) (Table 2).
The clear distinction between intracellular McSA1 and
pab27576 immunoreactivities was also evident at later
stages of the amyloid pathology (Additional file 2: Figure
S1). Pearson coefficients ranged between 0.35 and 0.5 and
there was approximately ~ 20 - 40% overlap between the
two signals in the brain regions investigated (Table 2). At
this time point, we also observed the presence of extracel-
lular amyloid deposits that were McSA1 positive but
pab27576 negative (Additional file 3: Figure S2c).
Strikingly, the intracellular McSA1 immunolabeling
appeared diffusely distributed throughout the neuronal
Figure 1 Temporal progression of the AD-like amyloid pathology in McGill-R-Thy1-APP transgenic rats. Intense intraneuronal Aβ
immunoreactivity is observed in McGill transgenic rats throughout the neocortex (a-c, g-i, o), hippocampus (a-f, n) and amygdala (j-l), as
detected with the anti-Aβ McSA1 monoclonal antibody. Note the absence of amyloid plaques at 3 months and 7 months of age. At 13
months, transgenic rats exhibited strong intracellular and extracellular McSA1 immunoreactivity. Abundant amyloid plaque deposition is evident
throughout all cortical layers, hippocampal formation and amygdala in homozygote transgenic rats. Arrows indicate the presence of amyloid
plaques. McSA1 immunoreactivity remained limited to the intracellular compartment in heterozygote animals. Note the absence of
McSA1-immunoreactivity in non-transgenic animals (m). Scale bar: a-c, m = 500 μm; d-l, n-o = 100 μm.
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ciated to vesicular-like structures within the perinuclear
region (Figure 2 and Additional file 2: Figure S1). To
obtain a higher, optimal 3D resolution of McSA1 and
pab27576 immunoreactivities at the pre-plaque stage, we
applied super-resolution SIM microscopy. With this tech-
nique, we finally demonstrate that the overlap between
McSA1 and pab27576 immunoreactive sites was minimal,
where the former diffuse McSA1 signal now becamelocalized to small intracellular vesicles, clearly dissociated
from pab27576 immunoreactive structures (Figure 3). For
a better illustration of the dissociation between Aβ and
APP/CTF-specific signals, a 3D model was generated fol-
lowing image reconstruction and registration and assem-
bly of serial z planes (Additional file 1: Video).
To further validate our inclusion/exclusion co-localization
analysis we then stained rat brain sections with MAOB-2, a
monoclonal antibody directed to residues 1–4 of Aβ, and
Figure 2 Detection of intraneuronal Aβ and APP/CTFs. a) To measure the overlap coefficient of different antibody binding sites, the signals
were separated from background using a brightness criterion and made binary. The two images were then superimposed; the M1 coefficient
represents the overlap (yellow) divided by the total green signal (yellow + green). The M2 coefficient represents the overlap divided by the total
red signal (yellow + red). b-d) Representative high-magnification confocal micrographs depicting co-localization between pab27576 (red) and b)
McSA1 (green) binding sites, c) MOAB-2 (green) and d) Nu1 (green) in lamina V neurons of the parietal cortex, at the pre-plaque stage
(3 month-old transgenic rats). Note the lack of complete overlap between Aβ- and APP/CTF-specific signals. Scale bar = 10 μm.
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APP or CTFs [39]. In general, the MOAB-2 immunoreaction
ranged from low (in some neurons) to hardly detectable in
most neurons from the different areas and time points ex-
amined. Therefore, we subjected confocal images to quanti-
tative co-localization analysis only when the MOAB-2 signal
was strong enough to be clearly distinguished from back-
ground, non-specific staining. Corroborating our previousresults with McSA1, we observed a differential pattern
of immunoreactivity between MOAB-2 and pab27576 in
cells with detectable and reliable MOAB-2 staining. At
3 months of age (pre-plaque) high-magnification quan-
titative co-localization analysis revealed only a partial
overlap between the two signals in neurons from lamina
V (Figure 2c), as reflected by an average Pearson coeffi-
cient of 0.41 ± 0.01 and M1 coefficient of 0.44 ± 0.02. At
Table 2 Co-localization analysis between McSA1 and
pab27576
Pearson Manders M1 Manders M2
3 months
CA1 0.57 ± 0.02 0.48 ± 0.02 0.83 ± 0.02
Lamina V 0.44 ± 0.03 0.30 ± 0.03 0.65 ± 0.04
Lamina III 0.32 ± 0.03 0.23 ± 0.03 0.56 ± 0.04
13 months
CA1 0.51 ± 0.04 0.37 ± 0.02 0.79 ± 0.03
Lamina V 0.39 ± 0.03 0.22 ± 0.02 0.74 ± 0.03
Lamina III 0.35 ± 0.03 0.22 ± 0.02 0.64 ± 0.04
M1: proportion of McSA1-IR (green) overlapping pab27576 (red) over its
total intensity.
M2: proportion of pab27576 (red) overlapping McSA1-IR (green) over its
total intensity.
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bel was hardly detectable in pyramidal neurons adjacent
to amyloid plaques, the latter which were strongly la-
beled by this antibody and not by pab27576 (Additional
file 3: Figure S2 a-b).
Additional confirmation of the segregation between
Aβ-specific and APP/CTF-specific signals was obtained
by co-labeling transgenic rat brain sections with the Nu1
monoclonal antibody (conformational, Aβ oligomer-specific)
[40] and pab27576. With this approach, a similar clear
distinction between Aβ-specific and APP/CTF-specific
intraneuronal signals was observed. At the pre-plaque
stage (3 months) we revealed only a partial co-localization
between Nu1 and pab27576 immunoreactivity in neuronsFigure 3 Characterization of McSA1 and pab27576 immunoreactivitie
distribution of McSA1 and pab27576 signals, pyramidal neurons from lamin
3-month old amyloid-plaque free transgenic rats. Note the distinct intracell
pab27576 (red), denoting Aβ-amyloid peptides and APP/CTFs, respectively.
left to right are frontal and oblique views, followed by higher magnificationfrom lamina V (Figure 2d), indicated by an average Pear-
son coefficient of 0.53 ± 0.02 (Table 3). Quantitative ana-
lysis also demonstrated only ~40% overlap (M1 = 0.37 ±
0.02) between Nu1 and pab27576 signals in lamina V
pyramidal neurons (Table 3). Similar observations were
made in CA1 and lamina III (Additional file 4: Figure
S3), revealing Pearson coefficients of 0.64 ± 0.01 and
0.35 ± 0.02 and a degree of overlap of ~ 25 – 50% between
the two signals (M1 = 0.50 ± 0.02 and M1 = 0.24 ± 0.02; re-
spectively) (Table 3). At 13 months of age co-localization
analysis further revealed a clear distinction between intra-
cellular Nu1 and pab27576 immunoreactivity (Additional
file 4: Figure S3). Pearson coefficients ranged between
0.4 - 0.7 throughout the three brain regions and there
was approximately 40 - 50% overlap between the signals
(Table 3). At both stages of the amyloid pathology, the
intracellular Nu1 immunolabel appeared associated to
vesicle-like structures.
Analysis of Aβ peptides in brain
We further quantified the age-dependent accumulation of
Aβ peptides in McGill transgenic rat brain homogenates
by ELISA following established protocols [47,48]. We ob-
served significantly higher levels of soluble Aβ40 peptides
(~3 fold) in cortex and hippocampus from transgenic rats
compared to age-matched non-transgenic animals, at 3
months (p < 0.0001), 7 months (p < 0.001) and 13–15
months of age (p < 0.01) (Figure 4a). The levels of solubles by super-resolution microscopy. To further characterize the
a III and lamina V of the parietal cortex were imaged by SIM in
ular localization of McSA1 immunoreactivity (green) with that of
DAPI (gray) indicates the boundaries of the neuronal nucleus. From
images of 3D-reconstructions.
Table 3 Co-localization analysis between Nu1 and
pab27576
Pearson Manders M1 Manders M2
3 months
CA1 0.64 ± 0.01 0.50 ± 0.02 0.70 ± 0.02
Lamina V 0.53 ± 0.03 0.37 ± 0.02 0.61 ± 0.04
Lamina III 0.35 ± 0.02 0.24 ± 0.02 0.43 ± 0.03
13 months
CA1 0.63 ± 0.05 0.51 ± 0.03 0.84 ± 0.02
Lamina V 0.68 ± 0.04 0.49 ± 0.03 0.79 ± 0.03
Lamina III 0.47 ± 0.02 0.37 ± 0.02 0.56 ± 0.03
M1: proportion of Nu1-IR (green) overlapping pab27576 (red) over its
total intensity.
M2: proportion of pab27576 (red) overlapping Nu1-IR (green) over its
total intensity.
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tween transgenic rats at different stages of the amyloid
pathology, with an average of 50.2 ± 4.7 pg/mg total pro-
tein. Furthermore, cortical and hippocampal levels of
TBS-soluble Aβ42 peptides were slightly elevated in young
McGill transgenic rats (3 and 7 months) compared to
non-transgenic animals (Figure 4b), whereas substantiallyFigure 4 Quantification of Aβ40 and Aβ42 levels in cortex and hippoca
in cortex + hippocampus homogenates from non-transgenic (−/−), heteroz
(3 months, 7 months and 13–15 months) were quantified with specific G2-
pellets were extracted with 70% formic acid (FA) and after neutralization, c
W0-2 and G2-13/W0-2 ELISAs, respectively. Values were normalized to total
ANOVA, followed by Dunnett’s post-hoc test. *P < 0.01, **P < 0.001, ***P < 0
(across ages).more Aβ42 was found in 13–15 month-old transgenics
(171 ± 37.8 pg/mg protein, p < 0.0001). This data strongly
suggests an age-dependent accumulation of soluble Aβ42
peptides in McGill transgenic rats (p < 0.001). Notably,
levels of TBS-soluble Aβ40 and Aβ42 were slightly in-
creased in heterozygote (+/−) rats at 13–15 months of age
compared to non-transgenic littermates, though not sig-
nificantly (Figure 4a-b).
When analyzing the presence and levels of Aβ in FA
fractions we detected highest concentrations of Aβ40
(938.3 ± 313.9 pg/mg protein, p < 0.001) and Aβ42
(3246.1 ± 963.7 pg/mg protein, p < 0.0001) in transgenic
rats at 13–15 months of age compared to plaque-free trans-
genic rats (Figure 4c-d), with an average Aβ42/Aβ40 ratio of
6 ± 2. Thus, this data revealed that ~95% of the total Aβ40
and Aβ42 detected in the cortex and hippocampus of trans-
genic rat at the post-plaque stage required FA for
solubilization. There was no difference or age-dependent
increase in the level of TBS-soluble or FA-treated Aβ pep-
tides in cerebellum between non-transgenic and transgenic
animals (Additional file 5: Figure S4); a finding that is in
agreement with the human pathology [49].mpus by sandwich ELISA. TBS-soluble a) Aβ40 and b) Aβ42 levels
ygous (+/−) and homozygous transgenic (+/+) rats at different ages
10/W0-2 and G2-13/W0-2 sandwich ELISAs, respectively. TBS-insoluble
) Aβ40 and d) Aβ42 levels in FA fractions were assayed with G2-10/
protein concentration and expressed as means ± SEM. One-way
.0001 (across the same time point), #P < 0.01, ##P < 0.001, ###P < 0.0001
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In order to detect Aβ peptides in CSF, we immunoprecipi-
tated human Aβ with the W0-2 antibody (Table 1). MALDI-
MS analysis revealed the presence of Aβ42 (4513 Da), Aβ40
(4329 Da), Aβ39 (4230 Da) and Aβ38 (4131 Da) peptides in
CSF from McGill transgenic rats, both at pre- and post-
plaque stages of the amyloid pathology (Figure 5).
Notably, the pattern of CSF peptides was similar at
both time points and comparable to that observed in hu-
man CSF [50]; except for two observations: no Aβ37 was
detected in the CSF of McGill transgenic rats at any
time point and the Aβ38 signal was as strong as the Aβ40
signal, under these conditions. MALDI-MS analysis re-
vealed an absence of Aβ signal in non-transgenic animals
(Figure 5) at both time points, indicating that detected Aβ
peptides predominantly derive from the human APP
transgene expression or reflecting the low level of en-
dogenous rodent Aβ [51]. The masses identified as Aβ
peptides were absent when immunoprecipitation was per-
formed from PBS instead of CSF.
Early and progressive cognitive deficits in McGill-R-Thy1-APP
rats
Impaired fear conditioning
During auditory conditioning training (Figure 6a), 3 month-
old transgenic and non-transgenic animals exhibited low,Figure 5 MALDI-MS spectra of immunoprecipitated Aβ peptides from
the W0-2 antibody and further subjected to MALDI-MS analysis. Peaks corre
monoisotopic masses of 4130.0 Da, 4229.0 Da, 4328.2 Da and 4512.3 Da re
masses are predominantly due to the linear detection method used. Signa
from either protein-G sepharose, the antibody or other non-specific bindincomparable baseline freezing behavior. The initial presenta-
tion of the tone, before the foot-shock, did not result in in-
creased freezing behavior in any of the groups. Conversely,
we observed marked differences in fear response acquisition
between transgenic animals and non-transgenic littermates
during the post-shock phase (F2,21 = 17.03; p < 0.001).
In the fear conditioning paradigm, animals can also
learn to associate the environment with the aversive
stimulus; therefore, we tested contextual fear condition-
ing behavior 24 h later in the same arena, and compared
it to the average freezing response during the pre-training
habituation session (which averaged ~10% freezing). No
differences in freezing responses between non-transgenic
and transgenic rats were detected during contextual fear
conditioning testing at this early stage (F2,21 = 1.043; p >
0.05) (Figure 6b). Following contextual fear conditioning,
we then tested fear memory retrieval in response to an
auditory cue, within a different environment. All rats ex-
hibited low, comparable freezing responses at baseline.
However, upon tone presentation, McGill transgenic rats
manifested significant deficits in amygdala-dependent
auditory fear memory, compared to non-transgenic litter-
mates (F2,21 = 47.12; p < 0.001) (Figure 6c). Therefore, fear
conditioning deficits were detectable at early stages of the
amyloid pathology, in the absence of amyloid plaques.
At this early time-point, transgenic homozygotes andrat CSF. Aβ peptides were immunoprecipitated from rat CSF with
spond to signals for Aβ38, Aβ39, Aβ40 and Aβ42 with theoretical
spectively. Note that the differences in measured versus theoretical
ls observed in the non-transgenic animals and the PBS control result
g components of the CSF.
Figure 6 Impaired auditory fear conditioning in McGill-Thy1-APP transgenic rats. Freezing responses in a-c) 3 month-old and d-f) 13
month-old transgenic rats. Following two days of habituation and animal handling, auditory fear conditioning was tested (a, d) followed by
assessment of contextual fear conditioning 24 h later (b, e). The following day (48 hs after auditory conditioning), cued fear responses were
examined in a different arena (c, f). Note the progression of auditory and contextual fear conditioning deficits as the amyloid pathology
advanced from pre- to post-plaque stages. a, c, d, f) Two-Way ANOVA, followed by Bonferroni post-hoc test. b, e) One-Way ANOVA, followed by
Bonferroni post-hoc test. Error bars represent mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001.
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sponses throughout all test phases. However, with in-
creasing age and advancing amyloid pathology, fear
conditioning deficits severely progressed in homozygote
animals (Figure 6d-f ).
We observed marked differences in fear response ac-
quisition between transgenic and non-transgenic rats
during the post-shock phase at 13 months (Figure 6d).
Both heterozygote and homozygote rats exhibited lower
freezing responses compared to non-transgenic animals
(F2,19 = 13.59; p < 0.05 and p < 0.001). Non-transgenic an-
imals presented a significant increase in freezing behav-
ior, with respect to their baseline response (F2,14 = 25.6;
p < 0.001). There was a mild learning response in hetero-
zygote animals (F2,14 = 4.95; p < 0.05) with respect to
their baseline freezing behavior. Conversely, transgenic
homozygote rats exhibited significant fear conditioning
deficits as evidenced by comparable freezing levels through-
out all test phases (F2,10 = 1.01; p > 0.05). All animals exhib-
ited low, comparable freezing behavior at baseline and
during the initial presentation of the tone.
In 13-month old transgenic rats with advanced amyloid
pathology we revealed marked contextual fear conditioning
deficits in homozygote animals. Non-transgenic and trans-
genic heterozygote rats exhibited high freezing responses
(~70% and ~60% freezing, respectively) (Figure 6e). Con-
versely, freezing behavior was significantly lower in McGill
homozygote transgenic rats (F2,19 = 9.528; p < 0.01). Duringfear memory retrieval in a different context (Figure 6f), all
groups exhibited low, comparable baseline freezing. Upon
tone presentation, homozygote rats presented significantly
lower freezing responses compared to non-transgenic ani-
mals (F2,19 = 3.37; p < 0.05).
Importantly, at both time points examined, there were
no differences in locomotor activity and/or pain sensitiv-
ity between rat groups (Additional file 6: Figure S5), sug-
gesting that the reduced fear conditioning responses
(freezing behavior) in transgenic rats were not influ-
enced by any differences in sensitivity to pain or by in-
creased locomotion.
Impaired novel object recognition & location
In the novel object recognition test, McGill-R-Thy1-APP
rats were able to discriminate the novel object better than
chance levels (object recognition index = 0.2), however
they exhibited significantly lower object recognition indi-
ces compared to wild type animals (Figure 7). An impair-
ment in object recognition memory was detectable at
early stages of the amyloid pathology, months prior to
extracellular Aβ deposition (Figure 7a) in McGill trans-
genic rats (F2,19 = 10.61; p < 0.001 and p < 0.05, respectively).
Novel object location (Figure 7b) was also significantly
impaired in heterozygote animals at this early stage but,
despite the trend, did not appear significantly affected
in homozygote rats (F2,19 = 3.031; p < 0.05 and p > 0.05,
respectively). At 13 months of age, McGill transgenic
Figure 7 Deficits in Novel Object Recognition and Location task. In the novel object recognition test (NOR) the object discrimination ratio
was defined as the difference in exploration time for the novel object (in sec) divided by the total exploration time (in sec). a, c) McGill APP
transgenic rats exhibited lower recognition memory indices than wild type littermates at a) pre-plaque (3 months) and c) post-plaque (13 months)
stages. In the novel object location test (NOL) (b, d) the object discrimination ratio was defined as the difference in exploration time for the
displaced object (sec) divided by the total exploration time (in sec). Data is expressed as mean ± SEM and analyzed with One-Way ANOVA,
followed by Tukey’s post hoc test; *P < 0.05, **P < 0.01, ***P < 0.001.
Iulita et al. Acta Neuropathologica Communications 2014, 2:61 Page 12 of 17
http://www.actaneurocomms.org/content/2/1/61heterozygote and homozygote rats showed significant
impairments in object recognition (Figure 7c, F2,21 =
13.87; p < 0.001), with recognition indices close to chance
levels, as well as deficits in location memory (Figure 7d,
F2,21 = 16.41; p < 0.001), compared to non-transgenic
animals.
Discussion
The concept that Aβ accumulates within neurons re-
mains a matter of controversial debate. However, it is
widely accepted that a central event in AD pathogenesis
is the abnormal accumulation of Aβ and its related
toxins, either due to increased production or to deficits
in clearance mechanisms [52,53]. Aβ peptides, initially
discovered extracellularly, are the core component of
amyloid plaques in AD and DS brains [54,55]. Severalstudies have reported the existence of intracellular Aβ
within cultured neurons [36,56-59] as well as in post-
mortem brains from AD [14,16,60], DS subjects [17-19]
and in transgenic rodent models [10,12,13,61,62].
Despite the above-mentioned studies, a valid concern
has been raised regarding some of the antibodies applied
for intracellular Aβ immunodetection, which could the-
oretically also recognize the Aβ sequence as part of APP
and in CTFs. This argument was recently put forward in
a study by Winton and colleagues who further con-
cluded that the intraneuronal material in the well-
established 3xTg-AD mouse model is not Aβ but in fact,
solely APP [30]. The idea that only APP accumulates
intraneuronally is thought-provoking and additionally,
whether the intracellular Aβ pathology causes some of
the symptoms in human AD remains unknown.
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that accumulate intraneuronally in McGill-R-Thy1-APP
rats and examined in parallel the presence of cognitive im-
pairments, in a model which is closer to the human path-
ology than transgenic mice. To investigate the intracellular
Aβ pathology, we have performed high-magnification quan-
titative co-localization/exclusion analysis, using three differ-
ent monoclonal antibodies specific for Aβ: 1) McSA1,
against Aβ residues 1–12; 2) MOAB-2, against Aβ residues
1–4 and 3) Nu1, a conformation-specific antibody which
recognizes Aβ oligomers [40]. These antibodies were co-
incubated with a polyclonal antibody (pab27576) against
the C-terminal domain of full-length APP. The present
study revealed a consistent subcellular segregation of im-
munoreactive sites detected by Aβ-specific antibodies and
pab27576 within neurons of different brain areas, at pre-
and post-plaque stages of the amyloid pathology. Import-
antly, our co-localization/exclusion analysis also revealed
that the intracellularly accumulated material is likely a het-
erogeneous mixture of Aβ, APP and CTFs.
The examination of the amyloid pathology with
super-resolution microscopy permitted us to further re-
veal a clear separation of the subcellular location of Aβ-
immunoreactivity from that of APP/CTFs. Similar com-
pelling evidence supporting the existence of bonafide
intraneuronal Aβ peptides has been provided by ELISA
analysis on laser microdissected pyramidal neurons
from sporadic AD cases [63]. Future studies of this na-
ture are warranted in the McGill-R-Thy1-APP model.
We have observed a certain degree of overlap between
Aβ antibodies and pab27576 by confocal microscopy. This
likely reflects the presence of Aβ and APP/CTFs within
the same intracellular location but does not necessarily
imply that the antibodies are identifying the same mole-
cules. In the experimental conditions employed for the
confocal imaging, the resolution was of 250 nm in the x, y
planes, and 700 nm in z; an area sufficient to accommo-
date thousands of molecules and even neighboring organ-
elles. Notably, when the McSA1 and pab27576 signals
were resolved by SIM, McSA1 immunoreactivity became
almost completely dissociated from pab27576 and was
found in distinct compartments. It should be kept in
mind, however, that this super-resolution technique also
has its limitations. Because the mathematical algorithms
reconstruct images based on Moiré patterns caused by the
structured illumination, the technique is less effective at
reassigning signal that is diffuse or weak. It is then pos-
sible that we have failed to detect low levels of Aβ or APP
at plasma membrane locations.
Previous work on the McGill-R-Thy1-APP transgenic
rat has provided additional evidence to support that a
considerable component of the intracellular material de-
tected by McSA1 is Aβ. Pre-adsorption of this antibody
with synthetic Aβ42 completely abolished McSA1immunoreactivity. Conversely, incubation with the same
molar concentration of a cleaved fragment of APP did
not result in diminished signal intensity [11], reinforcing
the specificity of the McSA1 antibody for Aβ compared
to APP-derived peptides [36].
In this study, we further observed that the intraneuro-
nal Aβ-specific immunolabel was hardly detectable in
close proximity to amyloid deposits. One interpretation
could be that the intracellular pool of Aβ may act as a
source for the formation of extracellular amyloid de-
posits [14]. Notably, in DS brains intracellular Aβ immu-
noreactivity diminishes with increasing age and advanced
AD pathology [18,19]. Furthermore, in brains from APP
transgenic mice conformation-specific antibodies have re-
vealed the early appearance of intraneuronal fibrillar and
oligomeric Aβ immunoreactivity, which declined as amyl-
oid plaques appeared, and further became evident in the
extracellular space [10]. Alternatively, the apparent decline
in intracellular Aβ signal may be the result of the intense
reactivity of extracellular Aβ, potentially sequestering anti-
bodies and creating steric hindrance, thus lowering the
availability of intracellular epitopes.
The biochemical data presented in this report indicates
that soluble Aβ40 and Aβ42 peptides are already abun-
dant during amyloid plaque-free stages. We assert that
this material reflects true Aβ (cleaved from APP), as the
ELISA approach applied in this study consisted of C-
terminus specific anti-Aβ capture antibodies, which do
not recognize CTFs or APP molecules. In the McGill
transgenic rat, ELISA analysis revealed robust accumula-
tion of soluble Aβ species at 3 and 7 months of age (in
cortex and hippocampus), with a preferential progressive
and incremental accumulation of Aβ42 compared to
Aβ40 peptides at advanced ages. Such a situation is simi-
lar to that observed in human AD and DS brains
[16,18,64]. This finding is of great significance consider-
ing that cognitive deficits paralleled the early accumula-
tion of soluble Aβ peptides and further progressed
across age and with the advancement of the soluble
Aβ42 pathology.
To further address this issue, we analyzed whether there
was an association between the average concentrations of
Aβ peptides and the magnitude of behavior deficits, across
the temporal progression of the amyloid pathology in
transgenic animals. We calculated a cognitive index, add-
ing the scores obtained throughout the different phases of
the two behavioral paradigms employed, and expressing
them as a z score. This analysis revealed a trend reflecting
that higher concentrations of soluble Aβ42 peptides cor-
related with lower indices of cognitive performance
(Figure 8a). No such correlation was evident for soluble
Aβ40 peptides (Figure 8b) or insoluble Aβ42 (Figure 8c).
However, there was a significant association between
the levels of insoluble Aβ40 peptides and cognitive
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cannot establish causality it is consistent with the con-
cept that soluble forms of Aβ42 are highly toxic species.
To determine the occurrence of Aβ peptides in the rat
CSF we resorted to Aβ immunoprecipiation followed by
MALDI-MS analysis, before and after the formation of
amyloid deposits. This technique allowed the detection
of C-terminally truncated peptides, including Aβ38,
Aβ39, Aβ40 and Aβ42 species, as early as 3 months of
age; a time point which precedes amyloid plaque depos-
ition by several months (4–6 months). The distinct pat-
tern of Aβ peptides observed in rat CSF compared to
human CSF (which includes more species, ranging from
1–12 to 1–42) may reflect differences in the γ-secretase
complex or differential Aβ clearance patterns between
human and rodent species. Importantly, this is one of
the first reports applying Aβ immunoprecipitation
followed by MALDI-MS analysis in CSF from a trans-
genic AD model, providing a robust, novel platform for
the assessment of Aβ expression profiles in biological
fluids of transgenic models. Furthermore, the CSF detec-
tion of Aβ peptides suggest a dynamic state of these
molecules, where some accumulate inside neurons, and
some are exported to the extracellular space, from whereFigure 8 Link between soluble Aβ pathology and cognitive impairme
insoluble (c, d) Aβ42 and Aβ40 and the magnitude of cognitive impairment
AD-like amyloid pathology. A cognitive index was calculated based on the
paradigms employed, and expressed as a z score. Average values were ana
cognition and the levels of soluble Aβ42 peptides but not with soluble Aβ4they can reach the CSF even in the absence of amyloid
plaques in the brain parenchyma.
A good number of previous studies support the tenet
that the occurrence of intraneuronal Aβ accumulation
can have early, deleterious effects in CNS functions
[8,12,61,65]. In our study, we observed strong Aβ-
immunoreactivity in the amygdala at pre-plaque (intra-
neuronal) and post-plaque stages; changes which likely
account for the fear conditioning deficits reported at
both time points. Emotional disturbances are a common
early symptom in AD patients and such changes may be
a reflection of early amygdalar damage [66,67]. The fact
that cognitive impairments were seen at the pre-plaque
stage, where Aβ could be detected intraneuronally (by
IHC) and in CSF (by MALDI-MS), suggests that a com-
bination of intraneuronal and soluble extracellular Aβ
may be responsible for impairing neuronal function at
early time points. A role for Aβ-mediated toxicity is fur-
ther supported by the fact that cognitive deficits pro-
gressed according with the incremental accumulation of
the amyloid pathology, in particular, increased levels of
soluble Aβ42 (Figure 8a). However, we do not discard
the possibility that the presence of other intracellular
species, such as CTFs may also contribute to neuronalnt. Correlation between average levels of soluble (a, b) and
s in transgenic animals, during the temporal progression of the
animals’ performance throughout all phases of the two behavioral
lyzed with linear regression. Note the negative correlation between
0.
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toxic to primary rat hippocampal neurons in culture
[68], and is capable of inducing impairments in spatial
learning and working memory in vivo [69-71].
Finally, we propose that an analogous, intraneuronal
Aβ pathology during the pre-diagnostic stages of human
AD should also have a negative impact on cognitive
function. However, due to population-based tests and
the well-known aspect of neural reserve [72] such early
deficits may be difficult to reveal in the human species.
We therefore suggest that self-to-self assessments that
reflect a cognitive decline from an individual-adjusted
baseline may be required to detect early (and yet subtle)
memory deficits in pre-symptomatic human AD.
Conclusions
This study demonstrates that a considerable component
of the intracellular AD-like pathology in McGill-Thy1-
APP rats consists of Aβ peptides. The intracellular ma-
terial reflects a variety of molecular species, including
free Aβ, APP, CTFs as well as aggregated Aβ peptides in
the form of oligomers. Future investigations on this issue
are warranted, particularly to examine which form of Aβ
predominates within neurons and in which compart-
ment; as well as dissecting the differential contributions
of intraneuronal species to the development and pro-
gression of CNS dysfunction. A similar pathological situ-
ation is likely to occur at the earliest, silent stages of AD
progression in the human brain.
Additional files
Additional file 1: Video. Following image reconstruction and
registration, serial z planes were assembled to form a 3D model using
the Volocity 3D Image Analysis Software. The video shows different
rotations and magnifications of the 3D model revealing a clear
dissociation between intraneuronal McSA1 (green) and pab27576 (red)
immunoreactivities.
Additional file 2: Figure S1. Double immunolabeling with McSA1 and
pab27576 antibodies. Representative high-magnification confocal
micrographs depicting lack of complete co-localization between
pab27576 (red) and McSA1 (green) immunoreactive sites at 3 months
and 13 months in CA1 neurons of the hippocampus, and neurons of
lamina V and III of the parietal cortex. Note the lack of complete overlap
between the intracellular Aβ- and APP/CTF-specific immunoreactive
signals at both time points. Scale bar = 10 μm.
Additional file 3: Figure S2. Double immunolabeling with MOAB-2,
McSA1 and pab27576. a-b) Representative high-magnification confocal
micrographs depicting co-localization between pab27576 (red) and
MOAB-2 (green) in CA1 neurons of the hippocampus a) and neurons of
lamina V of the parietal cortex b) at post-plaque stages (13 months). c)
Co-localization between McSA1 (green) and pab27576 (red) immunoreactive
sites in neurons of the cerebral cortex (lamina V) at 13 months. Note the
absence of pab27576 immunoreactivity in amyloid plaques (a-c). Scale
bar = 10 μm.
Additional file 4: Figure S3. Double immunolabeling with Nu1 and
pab27576. Representative high-magnification confocal micrographs
depicting lack of complete co-localization between pab27576 (APP/
CTF-specific sites, red) and Nu1 (Aβ oligomer-specific sites, green).These images illustrate CA1 neurons of the hippocampus and neurons
of lamina V and III of the parietal cortex from animals aged 3 and 13
months. Scale bar = 10 μm.
Additional file 5: Figure S4. Quantification of Aβ40 and Aβ42 levels by
ELISA in cerebellum. Aβ40 and Aβ42 levels in cerebellum homogenates
from non-transgenic (−/−), heterozygous (+/−) and homozygous
transgenic (+/+) rats at different ages (3 months, 7 months and 13–15
months) were quantified with specific G2-10/W0-2 and G2-13/W0-2
sandwich ELISAs, respectively. Values were normalized to total protein
concentration and expressed as means ± SEM. One-way ANOVA, followed
by Dunnett’s post-hoc test.
Additional file 6: Figure S5. Analysis of locomotor activity and pain
sensitivity in McGill transgenic rats. a, c) Freezing responses recorded
during a 5 min exploratory session in the testing environment. The
animals were allowed to explore the arena and returned to their home
cages. No stimuli were presented. b, d) Analysis of tactile sensitivity in the
rat hind paw using Von Frey filaments of increasing force. The graph
depicts the average withdrawal thresholds to mechanical stimulation,
expressed in grams of pressure. Data is expressed as mean ± SEM.
One-Way ANOVA, followed by Bonferroni post-hoc tests.
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